Skip to main content
. Author manuscript; available in PMC: 2015 May 29.
Published in final edited form as: Brain Behav Immun. 2013 Jun 28;33:112–122. doi: 10.1016/j.bbi.2013.06.004

Figure 2.

Figure 2

ATL313 reverses well-established neuropathic allodynia from chronic constriction injury performed 6 wk before administration (A). **P<0.0001 CCI+ATL313 10 pmol compared to CCI+vehicle, * P<0.05 CCI+ATL313 1 pmol compared to CCI+vehicle; n=6-7 rats/group. ATL313 dose-dependently reverses acute neuropathic allodynia from spinal nerve ligation (B). P< 0.01 for both doses of ATL313 compared to SNL+vehicle; n=5-8 rats/group. ATL313 reverses neuropathic allodynia induced by sciatic inflammatory neuropathy (C, 160 μg zymosan applied to the sciatic nerve on alternate days). P<0.001 compared to zymosan+vehicle; n=6-7 rats/group. All data are mean±SEM.